45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
62,244
Insurances with rates
21
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 108087544-2255320 | 67979-0002-01 - histrelin 50 mg Implan | $1,084,351 | $596,393 | — | — | 8 |
| 108087544-2255320 | 67979-0002-01 - histrelin 50 mg Implan | $1,084,351 | $542,176 | — | — | 23 |
| 108963946-2255320 | 69866-1025-01 - autologous cultured chondrocytes 0 | $1,045,524 | $575,038 | — | — | 8 |
| 108963946-2255320 | 69866-1025-01 - autologous cultured chondrocytes 0 | $1,045,524 | $522,762 | — | — | 23 |
| 108963947-2255320 | 69866-1030-05 - autologous cultured chondrocytes i | $1,045,524 | $575,038 | — | — | 8 |
| 108963947-2255320 | 69866-1030-05 - autologous cultured chondrocytes i | $1,045,524 | $522,762 | — | — | 23 |
| 108978003-2255320 | 69866-1030-08 - autologous cultured chondrocytes 1 | $1,045,524 | $575,038 | — | — | 8 |
| 108978003-2255320 | 69866-1030-08 - autologous cultured chondrocytes 1 | $1,045,524 | $522,762 | — | — | 23 |
| 108329173-2255325 | 71336-1001-01 - givosiran 189 mg/mL Soln | $405,600 | $223,080 | — | — | 8 |
| 108329173-2255325 | 71336-1001-01 - givosiran 189 mg/mL Soln | $405,600 | $202,800 | — | — | 23 |
| 109228707-2255322 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $374,655 | $206,060 | — | — | 8 |
| 109228707-2255322 | 00310-4535-30 - tremelimumab actl 20 mg/mL Soln | $374,655 | $187,327 | — | — | 23 |
| 1279402-2255325 | 00003-2328-22 - ipilimumab Soln | $354,454 | $194,950 | — | — | 8 |
| 1279402-2255325 | 00003-2328-22 - ipilimumab Soln | $354,454 | $177,227 | — | — | 23 |
| 108290516-2255322 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $297,380 | $163,559 | — | — | 8 |
| 108290516-2255322 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $297,380 | $148,690 | — | — | 23 |
| 104437516-2255325 | 75987-0080-10 - pegloticase 8 mg/mL Soln | $290,383 | $159,711 | — | — | 8 |
| 104437516-2255325 | 75987-0080-10 - pegloticase 8 mg/mL Soln | $290,383 | $145,191 | — | — | 23 |
| 1286149-2255325 | 54396-0801-01 - pegloticase Soln | $290,383 | $159,711 | — | — | 8 |
| 1286149-2255325 | 54396-0801-01 - pegloticase Soln | $290,383 | $145,191 | — | — | 23 |
| 108107889-2255325 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $265,598 | $146,079 | — | — | 8 |
| 108107889-2255325 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $265,598 | $132,799 | — | — | 23 |
| 1282361-2255325 | 57665-0002-02 - pegaspargase 3750. Soln | $265,598 | $146,079 | — | — | 8 |
| 1282361-2255325 | 57665-0002-02 - pegaspargase 3750. Soln | $265,598 | $132,799 | — | — | 23 |
| 1282362-2255325 | 54482-0301-01 - pegaspargase 3750. Soln | $265,598 | $146,079 | — | — | 8 |
| 1282362-2255325 | 54482-0301-01 - pegaspargase 3750. Soln | $265,598 | $132,799 | — | — | 23 |
| 108290269-2255322 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $253,006 | $139,153 | — | — | 8 |
| 108290269-2255322 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $253,006 | $126,503 | — | — | 23 |
| 1279159-2255319 | 63004-7731-01 - corticotropin 400. Soln | $248,174 | $136,496 | — | — | 8 |
| 1279159-2255319 | 63004-7731-01 - corticotropin 400. Soln | $248,174 | $124,087 | — | — | 23 |
| 108326359-2255325 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $244,206 | $134,313 | — | — | 8 |
| 108326359-2255325 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $244,206 | $122,103 | — | — | 23 |
| 1287035-2255322 | 76128-0155-75 - porfimer 75. mg REC Injection | $235,809 | $129,695 | — | — | 8 |
| 1287035-2255322 | 76128-0155-75 - porfimer 75. mg REC Injection | $235,809 | $117,905 | — | — | 23 |
| 108503656-2255322 | 72493-0103-03 - mitoMYcin 40 mg Kit | $227,705 | $125,238 | — | — | 8 |
| 108503656-2255322 | 72493-0103-03 - mitoMYcin 40 mg Kit | $227,705 | $113,853 | — | — | 23 |
| 1288223-2255323 | 00169-7050-01 - coagulation factor VIIa REC Inject | $222,752 | $122,514 | — | — | 8 |
| 1288223-2255323 | 00169-7050-01 - coagulation factor VIIa REC Inject | $222,752 | $111,376 | — | — | 23 |
| 108819334-2255322 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $213,606 | $117,483 | — | — | 8 |
| 108819334-2255322 | 00008-0100-01 - inotuzumab ozogamicin 0.9 mg Powde | $213,606 | $106,803 | — | — | 23 |
| 109148166-2255320 | 55566-9800-02 - fecal microbiota, live jslm Susp | $205,920 | $113,256 | — | — | 8 |
| 109148166-2255320 | 55566-9800-02 - fecal microbiota, live jslm Susp | $205,920 | $102,960 | — | — | 23 |
| 109124434-2255325 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $188,722 | $103,797 | — | — | 8 |
| 109124434-2255325 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $188,722 | $94,361 | — | — | 23 |
| 108031526-2255322 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $168,528 | $92,690 | — | — | 8 |
| 108031526-2255322 | 50242-0105-01 - polatuzumab vedotin 140 mg Powder | $168,528 | $84,264 | — | — | 23 |
| 108119581-2255325 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $165,339 | $90,937 | — | — | 8 |
| 108119581-2255325 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $165,339 | $82,670 | — | — | 23 |
| 108493398-2255319 | 50242-0922-01 - emicizumab 150 mg/mL Soln | $164,301 | $90,366 | — | — | 8 |
| 108493398-2255319 | 50242-0922-01 - emicizumab 150 mg/mL Soln | $164,301 | $82,151 | — | — | 23 |
Showing top 50 of 62,244 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.